What’s New in Antiretroviral Safety and Tolerability: Implications for Treatment

Download All
In this comprehensive online program led by expert faculty, review clinical strategies for applying the latest safety and tolerability data to minimize adverse events when selecting first-line ART and switching regimens in patients with HIV infection.
Todd T. Brown, MD, PhD
Daniel R. Kuritzkes, MD
Jordan E. Lake, MD, MSc
Brian Wood, MD


During the past 2 years, guidelines have shifted their recommendations on use of DTG around the time of conception and during pregnancy. As data and guidance evolve, which ART regimens should we recommend to PWH in these settings?

Brian Wood, MD Released: April 20, 2020

Certain INSTIs and TAF are associated with excessive weight gain in PWH. Here’s my take on what we know, what we don’t, and the need for clinical trials to assess mechanism and management strategies.

Jordan E. Lake, MD, MSc Released: April 27, 2020

Here’s my take on what clinicians who treat HIV need to know about bone loss risk and bone health screening in our patients.

Todd T. Brown, MD, PhD Released: September 8, 2020

Data from 2020 conferences have shed new light on the issues of ARV-associated weight gain and ART safety during conception and pregnancy. Here are expert answers to your outstanding questions.

Daniel R. Kuritzkes, MD Brian Wood, MD Released: December 7, 2020
Provided by USF Health

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Janssen Therapeutics, Division of Janssen Products, LP

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings